Traders should monitor the AAN presentation on April 21 for clinical data readouts, which could be a near-term catalyst. Absence of financials despite 'earnings' tag suggests this is a misclassified press release. Positive data could drive upside, but current lack of material financial information limits immediate trading impact.
Price Chart
Executive Summary
Rapport Therapeutics announced upcoming presentation of Phase 2a data for its lead candidate RAP-219 in focal onset seizures at the 2026 AAN Annual Meeting. The release contains no financial results or earnings data despite being tagged as an 'earnings' 8-K item, focusing solely on clinical trial updates.
Key Facts
- Rapport Therapeutics will present Phase 2a data for RAP-219 at the 2026 AAN Annual Meeting on April 21, 2026.
- Data to include efficacy and tolerability results, including 8-week follow-up from the trial.
- RAP-219 is a TARPγ8-specific AMPAR negative allosteric modulator with potential use in epilepsy, bipolar disorder, and neuropathic pain.
- No financial results, revenue, earnings, or guidance were disclosed in the release.
- Recent insider selling of $562K over the past 30 days.
Financial Impact
No financial impact disclosed — no revenue, earnings, or guidance provided.
Risk Factors
- Clinical data may not meet expectations, particularly on efficacy or safety.
- No commercial revenue or near-term path to profitability disclosed — company remains pre-revenue.
- Insider selling may signal lack of confidence ahead of data readout.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3266457 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 23, 2026 2d ago | Insider Cluster | $26.00 | awaiting T+5 | — | $25.93 (−0.27%) |
Oct 22, 2026 4d ago | Insider Cluster | $27.33 | awaiting T+5 | — | $25.93 (−5.12%) |
Oct 21, 2026 4d ago | Insider Buy | $26.53 | awaiting T+5 | — | $25.93 (−2.26%) |
Oct 20, 2026 6d ago | 8-K | $29.37 | awaiting T+5 | — | $25.93 (−11.71%) |
Oct 6, 2026 19d ago | 144 | $30.86 $28.33 | ▲ +8.20% | ▲ +7.22% | $25.93 (+15.98%) |
Oct 1, 2026 24d ago | Insider Cluster | $32.17 $30.65 | ▼ −4.72% | ▼ −5.89% | $25.93 (−19.40%) |
Aug 26, 2026 8w ago | Insider Cluster | $50.83 $47.65 | ▼ −6.26% | ▼ −6.52% | $25.93 (−48.99%) |
Aug 5, 2026 11w ago | 8-K | $42.44 $47.73 | ▲ +12.46% | ▲ +12.11% | $25.93 (−38.90%) |
Jul 1, 2026 16w ago | Insider Cluster | $38.97 $41.75 | ▲ +7.13% | ▲ +5.77% | $25.93 (−33.46%) |
Jun 30, 2026 16w ago | 144 | $39.39 $39.72 | ▲ +0.84% | ▲ +0.58% | $25.93 (−34.17%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers